Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs

Abstract

The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 triglyceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.

1 . An omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emulsion confers a protective benefit on cells against cell death following an hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight.  
   
   
       2 . The composition of  claim 1 , wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride.  
   
   
       3 . The composition of  claim 3 , wherein the omega-3 triglyceride and/or diglyceride comprises at least 40% EPA and/or DHA fatty acids.  
   
   
       4 . An omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emulsion confers a protective benefit on cells against cell death following an hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight, wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride and wherein the omega-3 triglyceride and/or diglyceride comprises at least 40% EPA and/or DHA fatty acids  
   
   
       5 . A method of limiting neurological damage resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection against neurological damage.  
   
   
       6 . A method of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection to limit cell death.  
   
   
       7 . The method of  claim 5  or  6  wherein the administration is either enteral or parenteral.  
   
   
       8 . The method of  claim 5  or  6  further comprising administering a conventional stroke treatment or preventative medication.  
   
   
       9 . The method of  claim 6  wherein the omega-3 lipid-based emulsion comprises at least 10% omega-3 oil, by weight.  
   
   
       10 . The method of  claim 6  wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight.  
   
   
       11 . The method of  claim 6  wherein the omega-3 oil comprises at least 10% omega-3 triglyceride and/or omega-3 diglyceride.  
   
   
       12 . The method of  claim 11  wherein the omega-3 triglyceride and/or omega-3 diglyceride comprise at least 40% EPA and/or DHA fatty acids.  
   
   
       13 . The method of  claim 6  wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride, and wherein the omega-3 triglyceride and/or diglyceride comprise at least 40% EPA and/or DHA fatty acids.  
   
   
       14 . The method of  claim 13  wherein the omega-3 lipid-based emulsion is administered at a dose of 0.05 g/kg to 4 g/kg.  
   
   
       15 . The method of  claim 6  wherein the omega-3 lipid-based emulsion is administered at 20 minutes to six hours after the hypoxic-ischemic insult.  
   
   
       16 . The method of  claim 6  wherein the omega-3 lipid-based formula is administered is 0-12 hours after the hypoxic-ischemic insult.  
   
   
       17 . The method of  claim 6  wherein the administration is followed by a later administration of the omega-3 lipid-based emulsion.  
   
   
       18 . The method of  claim 17  wherein the later administration is provided 1-24 hours after the hypoxic-ischemic insult.  
   
   
       19 . The method of  claim 18  wherein the later administration is provided 4 hours after the hypoxic-ischemic insult.  
   
   
       20 . The method of  claim 6 , wherein the ischemia has occurred in the organs selected from the group consisting of brain, lung, heart, kidney and large or small intestine.  
   
   
       21 . The method of  claim 5  wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride, and wherein the omega-3 triglyceride and/or diglyceride comprise at least 40% EPA and/or DHA fatty acids.